Key Points

  • Mutant TP53 MDS and sAML have altered regulation of select checkpoint molecules.

  • Targeting the proposed mir-34a-MYC-PDL1 circuit in patients with TP53 mutations represents a novel therapeutic strategy.

Abstract

Somatic gene mutations are key determinants of outcome in patients with myelodysplastic syndromes (MDS) and secondary AML (sAML). In particular, patients with TP53 mutations represent a distinct molecular cohort with uniformly poor prognosis. The precise pathogenetic mechanisms underlying these inferior outcomes have not been delineated. In this study, we characterized the immunological features of the malignant clone and alterations in the immune microenvironment in patients with TP53-mutant and wild-type MDS or sAML. Notably, PDL1 expression is significantly increased in hematopoietic stem cells of patients with TP53 mutations, which is associated with MYC upregulation and marked downregulation of MYC’s negative regulator miR-34a, a p53 transcription target. Notably, patients with TP53 mutations display significantly reduced numbers of bone marrow–infiltrating OX40+ cytotoxic T cells and helper T cells, as well as decreased ICOS+ and 4-1BB+ natural killer cells. Further, highly immunosuppressive regulatory T cells (Tregs) (ie, ICOShigh/PD-1) and myeloid-derived suppressor cells (PD-1low) are expanded in cases with TP53 mutations. Finally, a higher proportion of bone marrow–infiltrating ICOShigh/PD-1 Treg cells is a highly significant independent predictor of overall survival. We conclude that the microenvironment of TP53 mutant MDS and sAML has an immune-privileged, evasive phenotype that may be a primary driver of poor outcomes and submit that immunomodulatory therapeutic strategies may offer a benefit for this molecularly defined subpopulation.

REFERENCES

1.
Sallman
DA
,
Komrokji
R
,
Vaupel
C
, et al
.
Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes
.
Leukemia
.
2016
;
30
(
3
):
666
-
673
.
2.
Haase
D
,
Stevenson
KE
,
Neuberg
D
, et al;
International Working Group for MDS Molecular Prognostic Committee
.
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
.
Leukemia
.
2019
;
33
(
7
):
1747
-
1758
.
3.
Lindsley
RC
,
Saber
W
,
Mar
BG
, et al
.
Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation
.
N Engl J Med
.
2017
;
376
(
6
):
536
-
547
.
4.
Yoshizato
T
,
Nannya
Y
,
Atsuta
Y
, et al
.
Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation
.
Blood
.
2017
;
129
(
17
):
2347
-
2358
.
5.
Della Porta
MG
,
Gallì
A
,
Bacigalupo
A
, et al
.
Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation
.
J Clin Oncol
.
2016
;
34
(
30
):
3627
-
3637
.
6.
Montalban-Bravo
G
,
Takahashi
K
,
Garcia-Manero
G
.
Decitabine in TP53-Mutated AML
.
N Engl J Med
.
2017
;
376
(
8
):
796
-
797
.
7.
Bejar
R
,
Stevenson
KE
,
Caughey
B
, et al
.
Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation
.
J Clin Oncol
.
2014
;
32
(
25
):
2691
-
2698
.
8.
Freeman
GJ
,
Long
AJ
,
Iwai
Y
, et al
.
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
.
J Exp Med
.
2000
;
192
(
7
):
1027
-
1034
.
9.
Dong
H
,
Strome
SE
,
Salomao
DR
, et al
.
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion [Nat Med. 2002;8(9):1039]
.
Nat Med
.
2002
;
8
(
8
):
793
-
800
.
10.
Topalian
SL
,
Hodi
FS
,
Brahmer
JR
, et al
.
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
.
N Engl J Med
.
2012
;
366
(
26
):
2443
-
2454
.
11.
Brahmer
JR
,
Tykodi
SS
,
Chow
LQ
, et al
.
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
.
N Engl J Med
.
2012
;
366
(
26
):
2455
-
2465
.
12.
Davids
MS
,
Kim
HT
,
Bachireddy
P
, et al;
Leukemia and Lymphoma Society Blood Cancer Research Partnership
.
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
.
N Engl J Med
.
2016
;
375
(
2
):
143
-
153
.
13.
Albring
JC
,
Inselmann
S
,
Sauer
T
, et al
.
PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation
.
Bone Marrow Transplant
.
2017
;
52
(
2
):
317
-
320
.
14.
Yang
H
,
Bueso-Ramos
C
,
DiNardo
C
, et al
.
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
.
Leukemia
.
2014
;
28
(
6
):
1280
-
1288
.
15.
Kondo
A
,
Yamashita
T
,
Tamura
H
, et al
.
Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes
.
Blood
.
2010
;
116
(
7
):
1124
-
1131
.
16.
Chen
X
,
Liu
S
,
Wang
L
,
Zhang
W
,
Ji
Y
,
Ma
X
.
Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia
.
Cancer Biol Ther
.
2008
;
7
(
5
):
622
-
627
.
17.
Arber
DA
,
Orazi
A
,
Hasserjian
R
, et al
.
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
.
Blood
.
2016
;
127
(
20
):
2391
-
2405
.
18.
Greenberg
PL
,
Tuechler
H
,
Schanz
J
, et al
.
Revised International Prognostic Scoring System for myelodysplastic syndromes
.
Blood
.
2012
;
120
(
12
):
2454
-
2465
.
19.
Ley
TJ
,
Miller
C
,
Ding
L
, et al;
Cancer Genome Atlas Research Network
.
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia [published correction appears in N Engl J Med. 2013;369(1):98]
.
N Engl J Med
.
2013
;
368
(
22
):
2059
-
2074
.
20.
Haferlach
T
,
Kohlmann
A
,
Wieczorek
L
, et al
.
Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group
.
J Clin Oncol
.
2010
;
28
(
15
):
2529
-
2537
.
21.
Boettcher
S
,
Miller
PG
,
Sharma
R
, et al
.
A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies
.
Science
.
2019
;
365
(
6453
):
599
-
604
.
22.
Kikushige
Y
,
Miyamoto
T
,
Yuda
J
, et al
.
A TIM-3/Gal-9 Autocrine Stimulatory Loop Drives Self-Renewal of Human Myeloid Leukemia Stem Cells and Leukemic Progression
.
Cell Stem Cell
.
2015
;
17
(
3
):
341
-
352
.
23.
Velcheti
V
,
Schalper
KA
,
Carvajal
DE
, et al
.
Programmed death ligand-1 expression in non-small cell lung cancer
.
Lab Invest
.
2014
;
94
(
1
):
107
-
116
.
24.
Saft
L
,
Karimi
M
,
Ghaderi
M
, et al
.
p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)
.
Haematologica
.
2014
;
99
(
6
):
1041
-
1049
.
25.
Buchan
SL
,
Rogel
A
,
Al-Shamkhani
A
.
The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy
.
Blood
.
2018
;
131
(
1
):
39
-
48
.
26.
Amatore
F
,
Gorvel
L
,
Olive
D
.
Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy
.
Expert Opin Ther Targets
.
2018
;
22
(
4
):
343
-
351
.
27.
Zhang
B
,
Chikuma
S
,
Hori
S
,
Fagarasan
S
,
Honjo
T
.
Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model
.
Proc Natl Acad Sci USA
.
2016
;
113
(
30
):
8490
-
8495
.
28.
Lowther
DE
,
Goods
BA
,
Lucca
LE
, et al
.
PD-1 marks dysfunctional regulatory T cells in malignant gliomas
.
JCI Insight
.
2016
;
1
(
5
):
e85935
.
29.
Tu
JF
,
Ding
YH
,
Ying
XH
, et al
.
Regulatory T cells, especially ICOS+ FOXP3+ regulatory T cells, are increased in the hepatocellular carcinoma microenvironment and predict reduced survival
.
Sci Rep
.
2016
;
6
(
1
):
35056
.
30.
Casey
SC
,
Tong
L
,
Li
Y
, et al
.
MYC regulates the antitumor immune response through CD47 and PD-L1 [published correction appears in Science. 2016;352(6282):aaf7984]
.
Science
.
2016
;
352
(
6282
):
227
-
231
.
31.
Cortez
MA
,
Ivan
C
,
Valdecanas
D
, et al
.
PDL1 Regulation by p53 via miR-34
.
J Natl Cancer Inst
.
2015
;
108
(
1
):
108
.
32.
Yamamura
S
,
Saini
S
,
Majid
S
, et al
.
MicroRNA-34a modulates c-Myc transcriptional complexes to suppress malignancy in human prostate cancer cells
.
PLoS One
.
2012
;
7
(
1
):
e29722
.
33.
Choi
YJ
,
Lin
CP
,
Ho
JJ
, et al
.
miR-34 miRNAs provide a barrier for somatic cell reprogramming
.
Nat Cell Biol
.
2011
;
13
(
11
):
1353
-
1360
.
34.
Williams
P
,
Basu
S
,
Garcia-Manero
G
, et al
.
The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia
.
Cancer
.
2019
;
125
(
9
):
1470
-
1481
.
35.
Gros
A
,
Parkhurst
MR
,
Tran
E
, et al
.
Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients
.
Nat Med
.
2016
;
22
(
4
):
433
-
438
.
36.
Zajac
M
,
Zaleska
J
,
Dolnik
A
,
Bullinger
L
,
Giannopoulos
K
.
Expression of CD274 (PD-L1) is associated with unfavourable recurrent mutations in AML
.
Br J Haematol
.
2018
;
183
(
5
):
822
-
825
.
37.
Frazier
MW
,
He
X
,
Wang
J
,
Gu
Z
,
Cleveland
JL
,
Zambetti
GP
.
Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain
.
Mol Cell Biol
.
1998
;
18
(
7
):
3735
-
3743
.
38.
Cheng
P
,
Eksioglu
EA
,
Chen
X
, et al
.
S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes
.
Leukemia
.
2019
;
33
(
8
):
2034
-
2046
.
39.
Yamamura
S
,
Saini
S
,
Majid
S
, et al
.
MicroRNA-34a suppresses malignant transformation by targeting c-Myc transcriptional complexes in human renal cell carcinoma
.
Carcinogenesis
.
2012
;
33
(
2
):
294
-
300
.
40.
Wang
X
,
Li
J
,
Dong
K
, et al
.
Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia
.
Cell Signal
.
2015
;
27
(
3
):
443
-
452
.
41.
Sallman
DA
,
Asch
AS
,
Al Malki
MM
, et al
.
The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results [abstract]
.
Blood
.
2019
;
134
(
suppl 1
). Abstract 569.
42.
Welch
JS
,
Petti
AA
,
Miller
CA
, et al
.
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
.
N Engl J Med
.
2016
;
375
(
21
):
2023
-
2036
.
43.
Catherine Lai
JV
,
Reeder
S
,
Church
SE
, et al
.
TP53 abnormalities correlate with immune infiltration and are associated with response to flotetuzumab, an investigational immunotherapy, in acute myeloid leukemia
.
bioRxiv
.
2020
; doi:10.1101/2020.02.28.961391.
44.
Wang
Y
,
Wang
H
,
Yao
H
,
Li
C
,
Fang
JY
,
Xu
J
.
Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion
.
Front Pharmacol
.
2018
;
9
:
536
.
45.
Topalian
SL
,
Taube
JM
,
Anders
RA
,
Pardoll
DM
.
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
.
Nat Rev Cancer
.
2016
;
16
(
5
):
275
-
287
.
46.
Garcia-Manero
G
,
Sasaki
K
,
Montalban-Bravo
G
, et al
.
A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS) [abstract]
.
Blood
.
2018
;
132
(
suppl 1
). Abstract 465.
47.
Garcia-Manero
G
,
Montalban-Bravo
G
,
Sasaki
K
, et al
.
Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS) [abstract]
.
Blood
.
2018
;
132
(
suppl 1
). Abstract 1831.
48.
Daver
N
,
Kantarjian
H
,
Mackay
S
, et al
Polyfunctionality determined by single-cell proteomics of bone marrow-derived CD4 T cells from patients with acute myeloid leukemia identifies patients responding to anti-PD-1-based therapy and discovers profound T cell defect in mutant TP53 disease [abstract]
.
Cancer Res.
2019
;
79
.
Abstract LB-222
.
49.
Mo
L
,
Chen
Q
,
Zhang
X
, et al
.
Depletion of regulatory T cells by anti-ICOS antibody enhances anti-tumor immunity of tumor cell vaccine in prostate cancer
.
Vaccine
.
2017
;
35
(
43
):
5932
-
5938
.
50.
Szczepanski
MJ
,
Szajnik
M
,
Czystowska
M
, et al
.
Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia
.
Clin Cancer Res
.
2009
;
15
(
10
):
3325
-
3332
.
51.
Wang
X
,
Zheng
J
,
Liu
J
, et al
.
Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients
.
Eur J Haematol
.
2005
;
75
(
6
):
468
-
476
.
You do not currently have access to this content.

Sign in via your Institution

Sign In